Drug Profile
BBV 131
Alternative Names: BBV-131; HillcholLatest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator MSD Wellcome Trust Hilleman Laboratories
- Developer Bharat Biotech
- Class Cholera vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Cholera
Most Recent Events
- 04 Feb 2023 Bharat Biotech International Limited initiates a phase III Hillchol131 trial in Cholera (In infants, in adolescents, In children, In adults, In the elderly, Prevention) in India (PO) (NCT05732766)
- 22 Feb 2022 Phase-III clinical trials in Cholera (In infants, in adolescents, In children, In adults, In the elderly, Prevention) in India (PO) (NCT05507229)